查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1814895

人体生长荷尔蒙(HGH)的全球市场:各用途，各流通管道，各给药途径，企业分析(2025年～2033年)

Global Human Growth Hormone (HGH) Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球人类生长激素 (HGH) 市场规模及预测（2025-2033）

人类生长激素 (HGH) 市场预计将大幅扩张，预计到 2033 年将从 2024 年的 70.8 亿美元增至 168.6 亿美元。这意味着 2025 年至 2033 年的复合年增长率为 10.12%。推动这一成长的因素包括：人们对 HGH 的认识不断提高、生长障碍病例的增多，以及生物技术进步带来的治疗方法和市场机会的改善。

全球人类生长激素 (HGH) 市场展望

人类生长激素 (HGH) 是由脑下垂体分泌的一种胜肽类激素，可调节生长、代谢和细胞再生。它对儿童生长发育至关重要，影响身高和肌肉质量；对成年人而言，它影响多种身体功能，包括骨密度和身体组成。

过去十年，人类生长激素 (HGH) 因其所谓的抗衰老功效而日益受到欢迎，一些人开始利用它来促进健康、增加肌肉质量和减少体脂。运动员和健美运动员有时也会滥用 HGH 来提升运动表现。

HGH 的医疗用途是治疗儿童生长障碍和成人荷尔蒙缺乏症。然而，滥用 HGH 会导致严重的副作用，包括关节疼痛、胰岛素抗性和疾病易感性增加。随着人们对其风险认识的不断提高，人们正在持续努力，以负责任和道德的方式使用 HGH，并对其有效的治疗用途进行有效的医疗监督。

人类生长激素市场成长动力

生长激素缺乏症日益增多

人类生长激素 (hGH) 市场的主要成长动力之一是生长激素缺乏症 (GHD)、特纳氏症和慢性肾衰竭等生长障碍的盛行率不断上升。患有荷尔蒙缺乏症的儿童和成人需要定期接受 hGH 治疗，以维持正常的生长、代谢和整体健康。透过先进的基因和内分泌检测进行早期发现，进一步促进了患者的识别。随着医疗保健专业人员和家长意识的提高，接受 hGH 治疗的人数也不断增加。对治疗干预措施的需求不断增长，直接促进了全球人类生长激素市场的成长。根据 NCBI 的数据，在英国，大约每 3,500 至 4,000 名儿童中就有 1 名被诊断出患有儿童生长激素缺乏症。此外，该领域持续不断的研发也推动了生长激素市场的发展。例如，2022年2月，OPKO和辉瑞公司获得了欧盟对NGENLA（somatrogon）的上市许可，这是一种每週注射一次的药物，用于治疗儿童生长激素缺乏症。

药物传递技术的发展

药物传输技术的进步正在对hGH市场产生重大影响。传统上透过每日註射给药的生长激素疗法，现在正转向长效製剂、无针注射和笔式装置，旨在提高患者的依从性。皮下自动注射器因其易于使用和减少不适而越来越受欢迎。各公司也正在投资缓释製剂，以减少给药频率并提高治疗的便利性。这些发展不仅提高了儿科患者的依从性，也促进了成人患者的接受度，进一步提高了hGH疗法在国际医疗市场的渗透率。 2023年8月，美国食品药物管理局（FDA）批准Opko Health, Inc.和辉瑞公司联合研发的每週一次的生长激素（somatorogon）用于治疗儿童生长激素缺乏症。 Somatorogon-ghla（Ngenla）是一种长效注射剂型，根据3期临床试验数据，其在年身高增长速度方面不劣于生长激素。由于其安全性与生长激素相当，此次批准支持了Opko Health和辉瑞致力于透过创新治疗方案满足日益增长的儿童生长障碍需求的承诺。

本报告探讨了全球人类生长激素 (HGH) 市场，提供了成长动力和课题、细分市场分析以及关键公司分析。

目录

第1章 简介

第2章 调查和调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题

第5章 全球人体生长荷尔蒙(HGH)市场

  • 过去的市场趋势
  • 市场预测

第6章 市场占有率分析

  • 各用途
  • 各流通管道
  • 各给药途径
  • 各国

第7章 用途

  • 生长激素(GH)缺乏症
    • 市场分析
    • 市场规模与预测
  • 透纳氏症
    • 市场分析
    • 市场规模与预测
  • 原发性矮小症(ISS)
    • 市场分析
    • 市场规模与预测
  • 普瑞德威利症候群(PWS)
    • 市场分析
    • 市场规模与预测
  • SGA
    • 市场分析
    • 市场规模与预测
  • 其他
    • 市场分析
    • 市场规模与预测

第8章 流通管道

  • 医院药局
    • 市场分析
    • 市场规模与预测
  • 零售药局
    • 市场分析
    • 市场规模与预测
  • 线上药局
    • 市场分析
    • 市场规模与预测
  • 其他
    • 市场分析
    • 市场规模与预测

第9章 给药途径

  • 静脉
    • 市场分析
    • 市场规模与预测
  • 肌肉
    • 市场分析
    • 市场规模与预测
  • 皮下
    • 市场分析
    • 市场规模与预测
  • 口服
    • 市场分析
    • 市场规模与预测

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 澳洲
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第11章 价值链分析

第12章 波特的五力分析

第13章 SWOT分析

第14章 价格基准分析

  • Eli Lilly and Company
  • EMD Serono Inc.
  • F. Hoffmann-La Roche AG
  • Ferring B.V.
  • Genentech Inc.
  • Ipsen
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.

第15章 主要企业的分析

  • Eli Lilly and Company
  • EMD Serono Inc.
  • F. Hoffmann-La Roche AG
  • Ferring B.V.
  • Genentech Inc.
  • Ipsen
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
简介目录

Global Human Growth Hormone (HGH) Market Size & Forecast 2025-2033

Human Growth Hormone (HGH) market is expected to expand tremendously, with an estimated growth to US$ 16.86 billion by the year 2033 from US$ 7.08 billion in 2024. This increase represents a compound annual growth rate (CAGR) of 10.12% between 2025 and 2033. The growth is fueled by growing HGH awareness, elevated growth disorders, and development in biotechnology, which improves treatment and market opportunities.

Global Human Growth Hormone (HGH) Market Report by Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Small for Gestational Age, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Countries and Company Analysis, 2025-2033.

Global Human Growth Hormone (HGH) Market Outlook

Human Growth Hormone (HGH) is a peptide hormone secreted by the pituitary gland that is responsible for growth, metabolism, and regeneration of cells. It is important in childhood development, influencing height and muscling, and still affects multiple body functions in adults, including bone density and body composition.

Over the past decade, HGH has become increasingly popular for its supposed anti-aging effects, and some individuals have started using it to increase fitness, muscle mass, and decrease body fat. It is also abused by sports persons and bodybuilders to improve performance, even though there are strict laws against it in professional sports.

Medical applications of HGH are in the treatment of growth disorders in children and hormone deficiencies in adults. Misuse, though, can result in tremendous side effects, such as joint pains, insulin resistance, and enhanced disease vulnerability. As awareness of its risks increases, the effort continues to focus on effective medical oversight for valid therapeutic uses with a focus on using HGH responsibly and ethically.

Growth Drivers in the Human Growth Hormone Market

Growing Incidence of Growth Hormone Deficiencies

One of the key growth drivers of the hGH market is the growing incidence of growth disorders like growth hormone deficiency (GHD), Turner syndrome, and chronic renal insufficiency. Hormone-deficient children and adults need constant hGH therapy to help them grow normally, metabolize, and stay healthy. Early identification through the use of advanced genetic and endocrine testing is further fueling patient identification. With increased awareness among health practitioners and parents, increased numbers are being treated with hGH. Increased demand for therapeutic intervention directly contributes to global human growth hormone market growth. As per NCBI, pediatric growth hormone deficiency are diagnosed in about 1 in every 3,500-4,000 children in the UK. Further, the growth hormone market is also witnessing growth because of continuous research and development processes going on in this sector. For instance, in February 2022, OPKO and Pfizer received marketing authorization from the European Union for its Once-Weekly NGENLA (somatrogon) Injection, utilized in treating pediatric growth hormone deficiency.

Technological Developments in Drug Delivery

Technological advancements in drug delivery are heavily impacting the hGH market. Classically delivered through daily injections, growth hormone treatment is now moving towards long-duration formulations, needle-free injectors, and pen devices aimed at enhancing patient compliance. Auto-injectors for subcutaneous injections are becoming increasingly popular because of ease of use and less discomfort. Companies are also investing in sustained-release formulations to decrease dosing frequency and enhance convenience in treatment. These developments not only enhance compliance among pediatric patients but also boost acceptance in adults, further enhancing the penetration of hGH therapy in international healthcare markets. August 2023, FDA granted Opko Health, Inc. and Pfizer's once-weekly somatrogon approval for pediatric growth hormone deficiency, major players are tactically deepening their market presence. The long-acting injectable Somatrogon-ghla (Ngenla) shows noninferiority to somatropin in enhancing annual height velocity according to data from phase 3 trials. With a comparable safety profile to somatropin, this approval supports Opko Health and Pfizer's dedication to meeting children's need for growth failure treatment with innovative therapeutic options.

Widening Applications Beyond Pediatrics

Although hGH has been used conventionally among pediatric patients, its use in adults is increasing rapidly. Adult growth hormone deficiency, hormonal decline due to age, and off-label uses in metabolic disorders are widening the therapeutic applications of hGH. Research also shows promise in muscle wasting with HIV/AIDS and enhancing bone density. Growing approvals for use in adults and increasing health expenditures are driving adoption. With aging populations in developed nations, adult growth hormone therapy demand is expanding, offering new opportunities for pharmaceutical firms in the hGH market.

Challenges in the Human Growth Hormone Market

High Cost of Therapy

High expense of human growth hormone treatment is the principal barrier to access, especially in middle- and low-income nations. Most patients need long-term treatment, which can be as high as thousands of dollars per year. Even with insurance in developed markets, out-of-pocket costs are still high and act as a barrier for patients. In emerging markets, limited reimbursement policies add to the restrictions on adoption. The high expense also drives demand for biosimilars, but stringent regulation delays their release. Absent widely available cost-effective therapies, affordability will continue to be a key problem for sustainable growth in the hGH market.

Safety Issues and Regulator Restrictions

Safety issues related to long-term use of hGH provide another significant challenge. Possible side effects like edema, arthralgias, enhanced risk of diabetes, and cardiovascular problems evoke concern among physicians and regulators. Secondly, hGH abuse in athletics and bodybuilding has resulted in tight control and surveillance. Bureaucratic barriers to new product approvals combined with sophisticated production processes slow product entry and curtail innovation. These regulatory and safety constraints still hamper the broader implementation of hGH therapies, especially in areas with strict healthcare compliance regulations.

Growth Hormone (GH) Deficiency Market

The market for GH deficiency is one of the largest markets in the human growth hormone arena, fueled by both children and adults in need of long-term therapy. Earlier diagnosis through sophisticated endocrinology testing and genetic testing has enhanced treatment rates. Increasing awareness among parents, physicians, and policymakers has increased access to therapy. Pharmaceuticals are introducing new drug delivery devices to improve compliance in children. Nevertheless, elevated treatment prices and poor affordability in developing countries are challenges. Overall, increasing patient bases and improved diagnostic facilities are driving a steady growth in the GH deficiency segment.

Turner Syndrome Market

The Turner syndrome market is a large area of application for hGH therapy. Turner syndrome is a condition of short stature and delayed puberty in females, in which the use of growth hormone therapy plays a key role. Growing awareness, early detection, and enhanced access to pediatric endocrinologists have fueled treatment uptake. hGH therapy has a dramatic impact on height outcomes, enhancing patients' quality of life. Favorable reimbursement policy in developed nations also supports market growth. Treatment compliance issues and affordability constraints in the growing markets remain, though. With enhanced awareness and diagnostic solutions, the Turner syndrome hGH segment grows steadily.

Human Growth Hormone Hospital Market

Hospitals are a key distribution channel for hGH treatments, particularly among pediatric patients and complicated endocrine diseases. Hospitals offer the facilities for diagnosis, monitoring, and therapy administration, thus playing a key role in the adoption of hGH. Patients typically start treatment within hospital facilities before moving to outpatient treatment. The presence of high-quality injectors, qualified endocrinologists, and robust reimbursement support within hospitals reinforces the channel. Hospitals also have a significant role in clinical trials and the adoption of long-acting formulations. As healthcare infrastructure increases with growing patient populations, hospitals will remain at the forefront of stimulating high growth in the hGH market.

Human Growth Hormone Online Pharmacy Market

Online pharmacy is becoming a rapidly growing sales channel for hGH, fueled by convenience, affordability, and broad accessibility. Consumers with long-term prescriptions increasingly choose home delivery from web-based platforms for competitive prices and subscription refill. Online platforms also give consumers access to educational content, which improves treatment compliance. Expansion is strongest in developed markets where digital healthcare platforms are firmly entrenched. Concerns regarding spurious goods and government restrictions on online sale of prescription medication curbs broader implementation. As electronic healthcare grows worldwide, controlled e-pharmacies will be increasingly involved in hGH distribution.

Intravenous Human Growth Hormone Market

Intravenous (IV) hGH administration is less frequent but utilized in specialized hospital-based environments, such as in acute care or monitored settings. IV administration is suited for rapid absorption and therefore ideal for critical patients who need an instant hormone supplement. Nonetheless, it is not suitable for long-term treatment with regards to invasiveness and patient discomfort. Consequently, its application is limited mostly to hospitals and clinical trials environments. In spite of limited market presence, the IV hGH segment remains significant due to emergency care and specific medical cases. Future technology could make it more relevant, but subcutaneous administration currently prevails.

Subcutaneous Human Growth Hormone Market

Subcutaneous administration is the largest-selling method of delivery for hGH, taking the lion's share of market. It provides convenience, high bioavailability, and compatibility with newer auto-injectors and pen devices. Children and adult patients like subcutaneous injections for long-term therapy as it causes minimal discomfort and is convenient. Pharmaceutical companies are investing in long-acting products for weekly or monthly dosing to further enhance patient compliance. With robust uptake in hospital and homecare environments, subcutaneous delivery is the gold standard for hGH therapy, propelling the segment's ongoing growth worldwide.

United States Human Growth Hormone Market

United States is the largest hGH market, led by sophisticated health care infrastructure, high demand awareness, and extensive insurance coverage. Strong presence of major pharmaceuticals and ongoing R&D efforts in long-acting formulas bolstered market growth. Growing incidence of GH deficiency, Turner syndrome, and adult hormone deficiency drives demand. The U.S. is also a leading center for biosimilar development, driving patient access to cost-effective therapies. Strict regulatory systems surrounding safety and misuse monitoring are challenging but assuring of patient confidence. Pfizer Inc. and OPKO Health Inc. revealed that the FDA approved NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, for the treatment of pediatric patients three years and older with growth failure resulting from inadequate growth hormone secretion. NGENLA will be available for U.S. prescribing in August 2023.

France Human Growth Hormone Market

France's hGH market is favored by a robust public healthcare system and good reimbursement policies. Pediatric conditions like Turner syndrome and GH deficiency are the biggest drivers of demand. The nation also has an increasing adult population of patients needing hGH therapy for metabolic disorders. France engages actively in clinical research, which drives innovation in drug delivery systems and biosimilars. But strict controls and fears of misuse constrain growth. In spite of this, well-established healthcare infrastructure and government support place France among the strongest hGH markets in Europe.

India Human Growth Hormone Market

The hGH market in India is growing consistently, led by increasing awareness of pediatric growth disorders and improving access to endocrinology treatments. Growth is fueled by a strengthening healthcare infrastructure, rising medical tourism, and availability of affordable biosimilars. While affordability continues to be a challenge for most patients, high treatment expenses and low insurance coverage are keeping them from it. Private hospitals and e-pharmacies are becoming major channels of distribution. Increasing disposable income, urbanization, and government efforts to increase healthcare penetration are likely to drive market uptake. Feb 2025, The Health Minister has announced the introduction of growth hormone (GH) treatment under the State's KARE (Kerala United Against Rare Diseases) scheme, being a big leap in the management of rare diseases on World Rare Disease Day.

Brazil Human Growth Hormone Market

The hGH market in Brazil is expanding as a result of high importance given to pediatric care and government encouragement to the treatment of rare diseases. Government healthcare initiatives typically subsidize hGH treatments for Turner syndrome and GH deficiency, enhancing access among kids. Growing private healthcare adoption and recognition of adult GH shortages are also widening the demand. Yet, other problems like uneven healthcare infrastructure and regulatory delays are constraining faster growth. Jan 2024, With rising investment in biosimilars and growing middle-class populations, Cristalia's growth hormone products have recently been approved for commercialisation in Brazil Ratified by ANVISA1, CRISPEN is part of Nemera's state-of-the-art pen injector platform PENDURA AD.

Saudi Arabia Human Growth Hormone Market

The hGH market in Saudi Arabia is driven by increasing investments in healthcare infrastructure and government focus on improving pediatric and rare disease treatments. Increasing incidence of GH deficiency and Turner syndrome and high disposable incomes are favoring huge demand for hGH drugs. Hospitals are still the key distribution channel, although online pharmacies are becoming significant platforms. Nevertheless, reliance on imported drugs and high expenses of treatment are acting as roadblocks. Government-driven healthcare reforms pursuant to Vision 2030 will further increase access and affordability, making Saudi Arabia one of the quickest-expanding hGH markets in the Middle East.

Market Segmentation

Application

  • Growth Hormone (GH) Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature (ISS)
  • Prader-Willi Syndrome (PWS)
  • Small for Gestational Age
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Route of Administration

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral

Country

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa

All companies have been covered with 5 Viewpoints

  • Overviews
  • Key Person
  • Recent Developments
  • SWOT Analysis
  • Revenue Analysis

Key Players Analysis

1. Eli Lilly and Company

2. EMD Serono Inc.

3. F. Hoffmann-La Roche AG

4. Ferring B.V.

5. Genentech Inc.

6. Ipsen

7. Merck KGaA

8. Novartis AG

9. Novo Nordisk

10. Pfizer Inc.

Table of Contents

1. Introduction

2. Research & Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Human Growth Hormone (HGH) Market

  • 5.1 Historical Market Trends
  • 5.2 Market Forecast

6. Market Share Analysis

  • 6.1 By Application
  • 6.2 By Distribution Channel
  • 6.3 By Route of Administration
  • 6.4 By Countries

7. Application

  • 7.1 Growth Hormone (GH) Deficiency
    • 7.1.1 Market Analysis
    • 7.1.2 Market Size & Forecast
  • 7.2 Turner Syndrome
    • 7.2.1 Market Analysis
    • 7.2.2 Market Size & Forecast
  • 7.3 Idiopathic Short Stature (ISS)
    • 7.3.1 Market Analysis
    • 7.3.2 Market Size & Forecast
  • 7.4 Prader-Willi Syndrome (PWS)
    • 7.4.1 Market Analysis
    • 7.4.2 Market Size & Forecast
  • 7.5 Small for Gestational Age
    • 7.5.1 Market Analysis
    • 7.5.2 Market Size & Forecast
  • 7.6 Others
    • 7.6.1 Market Analysis
    • 7.6.2 Market Size & Forecast

8. Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Analysis
    • 8.1.2 Market Size & Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Analysis
    • 8.2.2 Market Size & Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Analysis
    • 8.3.2 Market Size & Forecast
  • 8.4 Others
    • 8.4.1 Market Analysis
    • 8.4.2 Market Size & Forecast

9. Route of Administration

  • 9.1 Intravenous
    • 9.1.1 Market Analysis
    • 9.1.2 Market Size & Forecast
  • 9.2 Intramuscular
    • 9.2.1 Market Analysis
    • 9.2.2 Market Size & Forecast
  • 9.3 Subcutaneous
    • 9.3.1 Market Analysis
    • 9.3.2 Market Size & Forecast
  • 9.4 Oral
    • 9.4.1 Market Analysis
    • 9.4.2 Market Size & Forecast

10. Countries

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Analysis
      • 10.1.1.2 Market Size & Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Analysis
      • 10.1.2.2 Market Size & Forecast
  • 10.2 Europe
    • 10.2.1 France
      • 10.2.1.1 Market Analysis
      • 10.2.1.2 Market Size & Forecast
    • 10.2.2 Germany
      • 10.2.2.1 Market Analysis
      • 10.2.2.2 Market Size & Forecast
    • 10.2.3 Italy
      • 10.2.3.1 Market Analysis
      • 10.2.3.2 Market Size & Forecast
    • 10.2.4 Spain
      • 10.2.4.1 Market Analysis
      • 10.2.4.2 Market Size & Forecast
    • 10.2.5 United Kingdom
      • 10.2.5.1 Market Analysis
      • 10.2.5.2 Market Size & Forecast
    • 10.2.6 Belgium
      • 10.2.6.1 Market Analysis
      • 10.2.6.2 Market Size & Forecast
    • 10.2.7 Netherlands
      • 10.2.7.1 Market Analysis
      • 10.2.7.2 Market Size & Forecast
    • 10.2.8 Turkey
      • 10.2.8.1 Market Analysis
      • 10.2.8.2 Market Size & Forecast
  • 10.3 Asia Pacific
    • 10.3.1 China
      • 10.3.1.1 Market Analysis
      • 10.3.1.2 Market Size & Forecast
    • 10.3.2 Japan
      • 10.3.2.1 Market Analysis
      • 10.3.2.2 Market Size & Forecast
    • 10.3.3 India
      • 10.3.3.1 Market Analysis
      • 10.3.3.2 Market Size & Forecast
    • 10.3.4 South Korea
      • 10.3.4.1 Market Analysis
      • 10.3.4.2 Market Size & Forecast
    • 10.3.5 Thailand
      • 10.3.5.1 Market Analysis
      • 10.3.5.2 Market Size & Forecast
    • 10.3.6 Malaysia
      • 10.3.6.1 Market Analysis
      • 10.3.6.2 Market Size & Forecast
    • 10.3.7 Indonesia
      • 10.3.7.1 Market Analysis
      • 10.3.7.2 Market Size & Forecast
    • 10.3.8 Australia
      • 10.3.8.1 Market Analysis
      • 10.3.8.2 Market Size & Forecast
    • 10.3.9 New Zealand
      • 10.3.9.1 Market Analysis
      • 10.3.9.2 Market Size & Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Analysis
      • 10.4.1.2 Market Size & Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Analysis
      • 10.4.2.2 Market Size & Forecast
    • 10.4.3 Argentina
      • 10.4.3.1 Market Analysis
      • 10.4.3.2 Market Size & Forecast
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
      • 10.5.1.1 Market Analysis
      • 10.5.1.2 Market Size & Forecast
    • 10.5.2 UAE
      • 10.5.2.1 Market Analysis
      • 10.5.2.2 Market Size & Forecast
    • 10.5.3 South Africa
      • 10.5.3.1 Market Analysis
      • 10.5.3.2 Market Size & Forecast

11. Value Chain Analysis

12. Porter's Five Forces Analysis

  • 12.1 Bargaining Power of Buyers
  • 12.2 Bargaining Power of Suppliers
  • 12.3 Degree of Competition
  • 12.4 Threat of New Entrants
  • 12.5 Threat of Substitutes

13. SWOT Analysis

  • 13.1 Strength
  • 13.2 Weakness
  • 13.3 Opportunity
  • 13.4 Threats

14. Pricing Benchmark Analysis

  • 14.1 Eli Lilly and Company
  • 14.2 EMD Serono Inc.
  • 14.3 F. Hoffmann-La Roche AG
  • 14.4 Ferring B.V.
  • 14.5 Genentech Inc.
  • 14.6 Ipsen
  • 14.7 Merck KGaA
  • 14.8 Novartis AG
  • 14.9 Novo Nordisk
  • 14.10 Pfizer Inc.

15. Key Players Analysis

  • 15.1 Eli Lilly and Company
    • 15.1.1 Overviews
    • 15.1.2 Key Person
    • 15.1.3 Recent Developments
    • 15.1.4 SWOT Analysis
    • 15.1.5 Revenue Analysis
  • 15.2 EMD Serono Inc.
    • 15.2.1 Overviews
    • 15.2.2 Key Person
    • 15.2.3 Recent Developments
    • 15.2.4 SWOT Analysis
    • 15.2.5 Revenue Analysis
  • 15.3 F. Hoffmann-La Roche AG
    • 15.3.1 Overviews
    • 15.3.2 Key Person
    • 15.3.3 Recent Developments
    • 15.3.4 SWOT Analysis
    • 15.3.5 Revenue Analysis
  • 15.4 Ferring B.V.
    • 15.4.1 Overviews
    • 15.4.2 Key Person
    • 15.4.3 Recent Developments
    • 15.4.4 SWOT Analysis
    • 15.4.5 Revenue Analysis
  • 15.5 Genentech Inc.
    • 15.5.1 Overviews
    • 15.5.2 Key Person
    • 15.5.3 Recent Developments
    • 15.5.4 SWOT Analysis
    • 15.5.5 Revenue Analysis
  • 15.6 Ipsen
    • 15.6.1 Overviews
    • 15.6.2 Key Person
    • 15.6.3 Recent Developments
    • 15.6.4 SWOT Analysis
    • 15.6.5 Revenue Analysis
  • 15.7 Merck KGaA
    • 15.7.1 Overviews
    • 15.7.2 Key Person
    • 15.7.3 Recent Developments
    • 15.7.4 SWOT Analysis
    • 15.7.5 Revenue Analysis
  • 15.8 Novartis AG
    • 15.8.1 Overviews
    • 15.8.2 Key Person
    • 15.8.3 Recent Developments
    • 15.8.4 SWOT Analysis
    • 15.8.5 Revenue Analysis
  • 15.9 Novo Nordisk
    • 15.9.1 Overviews
    • 15.9.2 Key Person
    • 15.9.3 Recent Developments
    • 15.9.4 SWOT Analysis
    • 15.9.5 Revenue Analysis
  • 15.10 Pfizer Inc.
    • 15.10.1 Overviews
    • 15.10.2 Key Person
    • 15.10.3 Recent Developments
    • 15.10.4 SWOT Analysis
    • 15.10.5 Revenue Analysis